NASDAQ:INO - Inovio Pharmaceuticals Stock Price, Price Target & More

$4.64 +0.01 (+0.22 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$4.64
Today's Range$4.58 - $4.73
52-Week Range$3.76 - $9.86
Volume901,967 shs
Average Volume986,736 shs
Market Capitalization$419.95 million
P/E Ratio-4.26
Dividend YieldN/A
Beta2.51

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200

Debt

Debt-to-Equity RatioN/A
Current Ratio3.91%
Quick Ratio3.91%

Price-To-Earnings

Trailing P/E Ratio-4.26
Forward P/E Ratio-4.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$42.22 million
Price / Sales9.97
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book2.94

Profitability

EPS (Most Recent Fiscal Year)($1.09)
Net Income$-88,200,000.00
Net Margins-208.92%
Return on Equity-66.07%
Return on Assets-50.18%

Miscellaneous

Employees280
Outstanding Shares90,700,000

How to Become a New Pot Stock Millionaire

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?

Inovio Pharmaceuticals declared a monthly dividend on Thursday, September 21st. Investors of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a yield of 17.84%. The ex-dividend date of this dividend is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. The biopharmaceutical company had revenue of $8.80 million for the quarter, compared to analyst estimates of $9.13 million. Inovio Pharmaceuticals had a negative net margin of 208.92% and a negative return on equity of 66.07%. Inovio Pharmaceuticals's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.35) earnings per share. View Inovio Pharmaceuticals' Earnings History.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Inovio Pharmaceuticals.

What price target have analysts set for INO?

10 Wall Street analysts have issued twelve-month target prices for Inovio Pharmaceuticals' shares. Their predictions range from $8.00 to $40.00. On average, they expect Inovio Pharmaceuticals' share price to reach $20.10 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
  • 2. Maxim Group analysts commented, "Inovio announced an amended agreement with ApolloBio (NEEQ: 430187) to develop and commercialize VGX-3100 for precancerous HPV (human papillomavirus) infections and dysplasias (cervical, vulvar, anal) in Greater China (China, Hong Kong, Macao, Taiwan, potentially Korea too). Inovio will receive an upfront payment of $23M plus milestones and royalties. The deal is expected to close in 1Q18." (1/2/2018)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:
  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Peter D. Kies, Chief Financial Officer (Age 53)
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
  • Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
  • George W. Bickerstaff III, Director (Age 62)
  • David B. Weiner, Director (Age 61)
  • Wendy L. Yarno, Director (Age 63)
  • Simon X. Benito, Independent Director (Age 72)

Has Inovio Pharmaceuticals been receiving favorable news coverage?

Media headlines about INO stock have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Inovio Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.07 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $4.64.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $419.95 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (INO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  601
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Inovio Pharmaceuticals (NASDAQ:INO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Inovio Pharmaceuticals in the last 12 months. Their average twelve-month price target is $20.10, suggesting that the stock has a possible upside of 333.19%. The high price target for INO is $40.00 and the low price target for INO is $8.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.802.80
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.10$20.10$20.20$20.20
Price Target Upside: 333.19% upside302.00% upside351.90% upside223.72% upside

Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History

Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018HC WainwrightSet Price TargetBuy$13.00HighView Rating Details
4/11/2018Maxim GroupSet Price TargetBuy$8.00MediumView Rating Details
3/15/2018Royal Bank of CanadaBoost Price TargetOutperform$11.00 -> $14.00HighView Rating Details
10/6/2017CitigroupInitiated CoverageBuy$10.00N/AView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper JaffrayUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies GroupReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
5/25/2016National Bank FinancialDowngradeOutperform Market Weight -> Sector Perform Market WeightN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Inovio Pharmaceuticals (NASDAQ:INO) Earnings History and Estimates Chart

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.07 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS

Inovio Pharmaceuticals (NASDAQ INO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.23)N/AView Earnings Details
3/14/2018Q4 17($0.30)($0.24)$9.13 million$8.80 millionViewListenView Earnings Details
11/8/2017Q3 17($0.25)($0.40)$10.27 million$2.60 millionViewN/AView Earnings Details
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/15/2014$0.22$0.22$4.63 million$4.66 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
5/7/2014$0.20$0.23$4.63 million$4.89 millionViewN/AView Earnings Details
3/22/2014$0.20$0.24ViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.08)($0.20)$1.60 million$0.79 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.16)$1.45 million$1.46 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.16)($0.08)ViewN/AView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.16)($0.17)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.16)($0.19)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.20)($0.16)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.12)($0.15)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.20)($0.09)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.09)ViewN/AView Earnings Details
3/17/2011Q4 2010($0.16)($0.24)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.12)($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.08)($0.30)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.16)($0.13)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.20)($0.28)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.20)($0.12)ViewN/AView Earnings Details
8/19/2009Q2 2009($0.24)($0.24)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.32)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.32)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.21)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.37)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.28)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.44)($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/21/2017Monthly$0.06909/28/20179/29/201710/16/2017
8/22/2017Monthly$0.06908/29/20178/31/20179/15/2017
7/25/2017Monthly$0.06907/27/20177/31/20178/15/2017
6/23/2017Monthly$0.06906/28/20176/30/20177/17/2017
(Data available from 1/1/2013 forward)

Insider Trades

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 31.50%
Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018David B WeinerDirectorSell9,000$4.91$44,190.00758,956View SEC Filing  
4/12/2018Jong Joseph KimCEOSell103,750$5.14$533,275.002,395,557View SEC Filing  
4/12/2018Simon X BenitoDirectorSell3,750$5.23$19,612.5031,548View SEC Filing  
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00740,956View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.202,164,887View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00142,291View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.0070,234View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00142,291View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.5024,048View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00127,291View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.0032,000View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.005,965,809View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00655,864View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Inovio Pharmaceuticals (NASDAQ INO) News Headlines

Source:
DateHeadline
Insider Selling: Inovio Pharmaceuticals Inc (INO) Director Sells 9,000 Shares of StockInsider Selling: Inovio Pharmaceuticals Inc (INO) Director Sells 9,000 Shares of Stock
www.americanbankingnews.com - April 19 at 7:52 PM
Inovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in StockInovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in Stock
www.americanbankingnews.com - April 13 at 7:27 PM
Inovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sells 103,750 SharesInovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sells 103,750 Shares
www.americanbankingnews.com - April 13 at 7:11 PM
Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 3:12 PM
Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC WainwrightInovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 12 at 11:17 AM
BLCM Surges As FDA Lifts Hold, SMMT Awaits Data In Q3, GEN Exits TexasBLCM Surges As FDA Lifts Hold, SMMT Awaits Data In Q3, GEN Exits Texas
www.nasdaq.com - April 12 at 5:15 AM
Inovio Pharmaceuticals (INO) PT Set at $12.00 by Maxim GroupInovio Pharmaceuticals (INO) PT Set at $12.00 by Maxim Group
www.americanbankingnews.com - April 11 at 11:52 PM
Inovio Pharma (INO) Awarded up to $56M from CEPIInovio Pharma (INO) Awarded up to $56M from CEPI
www.streetinsider.com - April 11 at 3:13 PM
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERSInovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
globenewswire.com - April 11 at 3:13 PM
$56 million deal: Inovio secures Coalition funding for vaccine candidates$56 million deal: Inovio secures Coalition funding for vaccine candidates
www.bizjournals.com - April 11 at 3:13 PM
Inovio Pharmaceuticals (INO) Given a $8.00 Price Target at Maxim GroupInovio Pharmaceuticals (INO) Given a $8.00 Price Target at Maxim Group
www.americanbankingnews.com - April 11 at 12:37 PM
Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Buy" by BrokeragesInovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:24 AM
Inovio Pharmaceuticals (INO) Rating Increased to Sell at ValuEngineInovio Pharmaceuticals (INO) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
Inovio Pharmaceuticals (INO) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowInovio Pharmaceuticals (INO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 3:01 PM
Inovio Pharmaceuticals (INO) Stock Rating Lowered by Zacks Investment ResearchInovio Pharmaceuticals (INO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price TargetHC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target
www.americanbankingnews.com - April 6 at 11:31 PM
Inovio Pharmaceuticals (INO) Coverage Initiated by Analysts at Royal Bank of CanadaInovio Pharmaceuticals (INO) Coverage Initiated by Analysts at Royal Bank of Canada
www.americanbankingnews.com - April 6 at 4:15 PM
Inovio Pharmaceuticals to Present at the HC Wainwright Annual Global Life Sciences ConferenceInovio Pharmaceuticals to Present at the HC Wainwright Annual Global Life Sciences Conference
globenewswire.com - April 3 at 5:09 AM
Inovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceInovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 2 at 3:13 PM
Inovio Pharmaceuticals (INO) "Buy" Rating Reiterated at HC WainwrightInovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM
Inovio Pharmaceuticals (INO) Upgraded by Zacks Investment Research to "Hold"Inovio Pharmaceuticals (INO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 29 at 10:49 PM
Inovio Pharmaceuticals (INO) Upgraded to Sell by ValuEngineInovio Pharmaceuticals (INO) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 26 at 5:58 PM
Inovios China Partnership License Agreement Should Be Cheered - Seeking AlphaInovio's China Partnership License Agreement Should Be Cheered - Seeking Alpha
seekingalpha.com - March 23 at 5:12 AM
Blog Exposure - Inovio Pharma Closed Collaboration Deal with ApolloBio to Develop and Commercialize VGX-3100 in Greater ChinaBlog Exposure - Inovio Pharma Closed Collaboration Deal with ApolloBio to Develop and Commercialize VGX-3100 in Greater China
finance.yahoo.com - March 22 at 3:13 PM
Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright AnalystsInovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 21 at 1:48 PM
Inovio Pharma (INO) Closes Pact with ApolloBio to Develop and ... - StreetInsider.comInovio Pharma (INO) Closes Pact with ApolloBio to Develop and ... - StreetInsider.com
www.streetinsider.com - March 20 at 3:10 PM
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater ChinaInovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
finance.yahoo.com - March 20 at 3:10 PM
$43M deal: Inovio finalizes restructured collaboration with Chinese biopharm firm$43M deal: Inovio finalizes restructured collaboration with Chinese biopharm firm
finance.yahoo.com - March 20 at 3:10 PM
Inovio Pharmaceuticals Inc (INO) Given Consensus Recommendation of "Buy" by BrokeragesInovio Pharmaceuticals Inc (INO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 1:52 AM
Maxim Group Analysts Give Inovio Pharmaceuticals (INO) a $8.00 Price TargetMaxim Group Analysts Give Inovio Pharmaceuticals (INO) a $8.00 Price Target
www.americanbankingnews.com - March 15 at 11:10 PM
Inovio Pharmaceuticals (INO) PT Set at $13.00 by HC WainwrightInovio Pharmaceuticals (INO) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - March 15 at 10:30 PM
Inovio Pharmaceuticals (INO) Price Target Increased to $14.00 by Analysts at Royal Bank of CanadaInovio Pharmaceuticals (INO) Price Target Increased to $14.00 by Analysts at Royal Bank of Canada
www.americanbankingnews.com - March 15 at 7:42 PM
Inovios (INO) Q4 Loss Narrower than Expected, Revenues Beat - NasdaqInovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat - Nasdaq
www.nasdaq.com - March 15 at 3:12 PM
Inovio's (INO) Q4 Loss Narrower than Expected, Revenues BeatInovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat
finance.yahoo.com - March 15 at 3:12 PM
Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End ... - GlobeNewswire (press release)Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 5:11 AM
Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year - NasdaqInovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year - Nasdaq
www.nasdaq.com - March 15 at 5:11 AM
Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year ... - Investorplace.comInovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year ... - Investorplace.com
investorplace.com - March 15 at 5:11 AM
Inovio Pharmaceuticals (INO) Raised to "Hold" at BidaskClubInovio Pharmaceuticals (INO) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 14 at 6:39 PM
Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-YearInovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year
investorplace.com - March 14 at 5:57 PM
Inovio Pharmaceuticals (INO) Issues Quarterly  Earnings Results, Beats Expectations By $0.06 EPSInovio Pharmaceuticals (INO) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - March 14 at 5:54 PM
Inovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV - StreetInsider.comInovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV - StreetInsider.com
www.streetinsider.com - March 14 at 3:11 PM
Earnings Preview For Inovio Pharmaceuticals - BenzingaEarnings Preview For Inovio Pharmaceuticals - Benzinga
www.benzinga.com - March 14 at 3:11 PM
Earnings Preview For Inovio PharmaceuticalsEarnings Preview For Inovio Pharmaceuticals
finance.yahoo.com - March 14 at 3:11 PM
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B InfectionInovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
finance.yahoo.com - March 14 at 3:11 PM
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018 - NasdaqInovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018 - Nasdaq
www.nasdaq.com - March 12 at 8:15 AM
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
finance.yahoo.com - March 12 at 8:15 AM
Inovio Pharmaceuticals (INO) Stock Rating Upgraded by BidaskClubInovio Pharmaceuticals (INO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 11 at 4:45 PM
Whats in the Cards for Inovio (INO) This Earnings Season? - NasdaqWhat's in the Cards for Inovio (INO) This Earnings Season? - Nasdaq
www.nasdaq.com - March 6 at 3:01 PM
What's in the Cards for Inovio (INO) This Earnings Season?What's in the Cards for Inovio (INO) This Earnings Season?
finance.yahoo.com - March 6 at 3:01 PM
Zacks: Analysts Anticipate Inovio Pharmaceuticals Inc (INO) Will Post Quarterly Sales of $7.75 MillionZacks: Analysts Anticipate Inovio Pharmaceuticals Inc (INO) Will Post Quarterly Sales of $7.75 Million
www.americanbankingnews.com - March 5 at 9:28 AM

SEC Filings

Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.